Ibrutinib shows similar real-world overall survival outcomes for high-risk and non-high-risk CLL/SLL patients, suggesting cytogenetic risk factors do not affect its efficacy. The study utilized a ...

Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...

Study met its primary endpoint, with TG-1101 (ublituximab) plus ibrutinib increasing Overall Response Rate (ORR) by >70% over ibrutinib alone The combination was well tolerated with a safety profile ...

During a live event, Andrew H. Lipsky, MD, and participants discuss emerging trial data and real-world applications of ...

MILAN — Response rates were robust in patients with refractory or relapsed chronic lymphocytic leukemia (CLL) who were treated with ABT-199/GDC-0199, an investigational selective inhibitor of B-cell ...

ATLANTA, Georgia — A novel investigational therapeutic agent appears to be an effective and safe treatment option for patients with chronic lymphocytic leukemia (CLL). According to 2 new studies ...

Hematologic precursor conditions include monoclonal gammopathy of undetermined significance (MGUS), monoclonal B-cell lymphocytosis (MBL), and clonal hematopoiesis (CH). These conditions are ...

The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal ...

Erratum: Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease The article by Davids ...